SHIRE PLC: Guidance Update

Guidance Update 
Dublin, Ireland - January 8, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) 
Angus Russell, Chief Executive Officer of Shire, will address investors today
at the JP Morgan Healthcare Conference in San Francisco. In his address he will
confirm that Shire expects to deliver double digit full year earnings growth
for 2012, and looking ahead, Shire is now increasingly confident of meeting
current consensus earnings expectations(1) for 2013. 
Angus' presentation will be webcast live today, at 11:00 AM PST/2:00 PM EST/7:
00 PM GMT 
Investors can access the live webcast here 
(1) Based on the most recent consensus estimates compiled by Consensus Forecast
Ltd, as of the date of this press release, of $6.69 Non GAAP diluted earnings
per ADS for the year ended 31 December 2013, included on Shire's website (http:
For further information please contact: 
Investor Relations                                                              
Eric Rojas                         +1 781 482 0999    
Sarah Elton-Farr               +44 1256 894157    
Jessica Mann                        +44 1256 894 280   
Gwen Fisher                       +1 484 595 9836    
Notes to editors 
Shire enables people with life-altering conditions to lead better lives. 
Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of: 
* Behavioral Health and Gastro Intestinal conditions 

      * Rare Diseases
      * Regenerative Medicine
    as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.


Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialize, the Company's results could be materially adversely
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company's Specialty
Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as
well as the ability to secure new products for commercialization and/or
development; government regulation of the Company's products; the Company's
ability to manufacture its products in sufficient quantities to meet demand;
the impact of competitive therapies on the Company's products; the Company's
ability to register, maintain and enforce patents and other intellectual
property rights relating to its products; the Company's ability to obtain and
maintain government and other third-party reimbursement for its products; and
other risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
-0- Jan/08/2013 17:00 GMT
Press spacebar to pause and continue. Press esc to stop.